Maria Gogou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Gogou has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Andreas Giannopoulos
Neuromuscular Disorders Unit, University Hospital AHEPA, Thessaloniki, Greece, Thessaloniki, Greece
8 shared publicationsEvangelos Pavlou
Neuromuscular Disorders Unit, University Hospital AHEPA, Thessaloniki, Greece, Thessaloniki, Greece
7 shared publicationsKaterina Haidopoulou
Neuromuscular Disorders Unit, University Hospital AHEPA, Thessaloniki, Greece, Thessaloniki, Greece
7 shared publicationsAthanasios Evangeliou
Fourth Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, General Hospital Papageorgiou, Thessaloniki, Greece
6 shared publicationsMaria Eboriadou
4th Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, General Hospital Papageorgiou, Thessaloniki, Greece
4 shared publicationsAnastasia Keivanidou
Department of Pediatric Cardiology, 2nd Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
3 shared publications
Latest Publications
- 26 September 2026
- Published by Elsevier in Epilepsy Research
- Vol. 228
Antiseizure medications in children with acute symptomatic seizures: A quality improvement project
- 26 September 2026
- Published by Elsevier in Epilepsy Research
- Vol. 228
Antiseizure medications in children with acute symptomatic seizures: A quality improvement project
- Open Access
- 21 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70687
Climate Change, Neurological Disorders and Brain Health: To‐Know Concepts and Future Actions by the EAN Environmental Influences in Neurology Task Force
Background and Purpose: While the estimation of the climate change effects is dependent on the models used, there is a growing consensus that emissions of greenhouse gases (GHG) cause global warming, resulting in the acceleration of climate change. The degree to which climate change is going to affect the nervous system of healthy individuals and how it may lead to an increase in the prevalence and burden of neurological disorders is presently incompletely understood and studied. It is imperative that the neurological community increases its awareness about climate change and strives for a clear evidence‐based consensus on the relationship between climate change and the negative consequences on brain health and neurological disorders. Methods: Part I provides a narrative overview of climate change in neurology, whereas Part II focuses on climate change action in neurology. Results: We provide clinicians and neuroscience stakeholders with tools to understand key concepts at the interface between climate change, neurological disorders, and brain health. Moreover, this paper states priorities in this field for the European Academy of Neurology, through the work of the Environmental Influences in Neurology Task Force, presenting 10 operational areas adapted from the WHO operational framework for building climate‐resilient and low‐carbon health systems . Conclusion: In the frame of its Brain Health Mission, the European Academy of Neurology is committed to supporting a neurology that is able to understand the impact of climate change and become a climate‐resilient neurology to promote health in general and brain health specifically.
- 21 August 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (8) , e70687
Open AccessClimate Change, Neurological Disorders and Brain Health: To‐Know Concepts and Future Actions by the EAN Environmental Influences in Neurology Task Force
Background and Purpose: While the estimation of the climate change effects is dependent on the models used, there is a growing consensus that emissions of greenhouse gases (GHG) cause global warming, resulting in the acceleration of climate change. The degree to which climate change is going to affect the nervous system of healthy individuals and how it may lead to an increase in the prevalence and burden of neurological disorders is presently incompletely understood and studied. It is imperative that the neurological community increases its awareness about climate change and strives for a clear evidence‐based consensus on the relationship between climate change and the negative consequences on brain health and neurological disorders. Methods: Part I provides a narrative overview of climate change in neurology, whereas Part II focuses on climate change action in neurology. Results: We provide clinicians and neuroscience stakeholders with tools to understand key concepts at the interface between climate change, neurological disorders, and brain health. Moreover, this paper states priorities in this field for the European Academy of Neurology, through the work of the Environmental Influences in Neurology Task Force, presenting 10 operational areas adapted from the WHO operational framework for building climate‐resilient and low‐carbon health systems . Conclusion: In the frame of its Brain Health Mission, the European Academy of Neurology is committed to supporting a neurology that is able to understand the impact of climate change and become a climate‐resilient neurology to promote health in general and brain health specifically.
- Open Access
- 14 April 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (3) , 710-718
ILAE ‐ YES global webinar series: Integrating clinical and basic science in epilepsy research
Summary: Bridging clinical and basic research is increasingly recognized as a priority in the epilepsy field, yet opportunities for integration remain limited by the time, space, and financial constraints of scientific meetings. To address this gap, the Research Task Force of the Young Epilepsy Section of the International League Against Epilepsy (ILAE‐YES) organized a free global webinar series designed to promote translational dialogue and provide accessible research education for early‐career clinicians, researchers, and physician‐scientists. Based on a preliminary ILAE‐YES community survey, eight topics of high interest were selected: (1) epigenetics, (2) EEG biomarkers, (3) ictogenesis, (4) thalamo‐cortical network, (5) sudden unexpected death in epilepsy, (6) neurodegeneration and seizures, (7) seizure‐related brain damage, and (8) neuromodulation therapy. From March to June 2025, eight live Zoom webinars were held, each featuring expert speakers representing both basic science and clinical perspectives, with recordings made available as unlisted YouTube videos to ensure on‐demand access. A total of 1199 individuals from 116 countries registered, 63.2% from low‐ and middle‐income countries. Live attendance averaged 50 participants per session, and the mean session duration was 71.6 min, including an average of 16 min of discussion. Post‐session feedback was obtained from 285 respondents; overall satisfaction was high, with 93.3% rating their experience as 4 or 5 on a 5‐point Likert scale. Speaker satisfaction was similarly high (95.4%), and 80.0% reported gaining new research ideas. Although access to YouTube and Google Forms may have limited participation in some regions, the series provided an inclusive and globally accessible platform. These findings demonstrated that free, discussion‐focused online webinars represent a scalable, low‐cost, and reproducible educational model that can effectively promote international engagement and integration between clinical and basic epilepsy research, aligning with the ILAE's global educational mission and complementing WHO IGAP priorities on capacity building and equitable access to knowledge. Plain Language Summary: Bringing together basic science and clinical research is important for improving epilepsy care, but many researchers have limited opportunities to learn across these fields. We organized a free global webinar series that helped early‐career clinicians and researchers learn about epilepsy research by combining scientific talks with clinical perspectives and open discussion. More than 1100 participants from over 100 countries joined, and most reported high satisfaction and gaining new research ideas. These results show that free, discussion‐based online webinars can provide an accessible way to support research education and international learning in epilepsy.
- 14 April 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (3) , 710-718
Open AccessILAE ‐ YES global webinar series: Integrating clinical and basic science in epilepsy research
Summary: Bridging clinical and basic research is increasingly recognized as a priority in the epilepsy field, yet opportunities for integration remain limited by the time, space, and financial constraints of scientific meetings. To address this gap, the Research Task Force of the Young Epilepsy Section of the International League Against Epilepsy (ILAE‐YES) organized a free global webinar series designed to promote translational dialogue and provide accessible research education for early‐career clinicians, researchers, and physician‐scientists. Based on a preliminary ILAE‐YES community survey, eight topics of high interest were selected: (1) epigenetics, (2) EEG biomarkers, (3) ictogenesis, (4) thalamo‐cortical network, (5) sudden unexpected death in epilepsy, (6) neurodegeneration and seizures, (7) seizure‐related brain damage, and (8) neuromodulation therapy. From March to June 2025, eight live Zoom webinars were held, each featuring expert speakers representing both basic science and clinical perspectives, with recordings made available as unlisted YouTube videos to ensure on‐demand access. A total of 1199 individuals from 116 countries registered, 63.2% from low‐ and middle‐income countries. Live attendance averaged 50 participants per session, and the mean session duration was 71.6 min, including an average of 16 min of discussion. Post‐session feedback was obtained from 285 respondents; overall satisfaction was high, with 93.3% rating their experience as 4 or 5 on a 5‐point Likert scale. Speaker satisfaction was similarly high (95.4%), and 80.0% reported gaining new research ideas. Although access to YouTube and Google Forms may have limited participation in some regions, the series provided an inclusive and globally accessible platform. These findings demonstrated that free, discussion‐focused online webinars represent a scalable, low‐cost, and reproducible educational model that can effectively promote international engagement and integration between clinical and basic epilepsy research, aligning with the ILAE's global educational mission and complementing WHO IGAP priorities on capacity building and equitable access to knowledge. Plain Language Summary: Bringing together basic science and clinical research is important for improving epilepsy care, but many researchers have limited opportunities to learn across these fields. We organized a free global webinar series that helped early‐career clinicians and researchers learn about epilepsy research by combining scientific talks with clinical perspectives and open discussion. More than 1100 participants from over 100 countries joined, and most reported high satisfaction and gaining new research ideas. These results show that free, discussion‐based online webinars can provide an accessible way to support research education and international learning in epilepsy.
- 25 September 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 110 (5) , 400-402
Children’s voices and the climate crisis: a report from the RCPCH
- 25 September 2024
- Published by BMJ in Archives of Disease in Childhood
- Vol. 110 (5) , 400-402
Children’s voices and the climate crisis: a report from the RCPCH
- 5 June 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 66 (8) , 1106-1107
From developmental neurology to brain health across the lifespan: Innovation in training, care, and public policy
This letter to the editor is a response to the editorial by Vollmer on pages 962–963 of this issue.
- 5 June 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 66 (8) , 1106-1107
From developmental neurology to brain health across the lifespan: Innovation in training, care, and public policy
This letter to the editor is a response to the editorial by Vollmer on pages 962–963 of this issue.
- 31 May 2023
- Published by Wiley in Epileptic Disorders
- Vol. 25 (4) , 586-589
Competency‐based epilepsy training: A comparison between U.S.‐based milestones and ILAE curriculum
- 31 May 2023
- Published by Wiley in Epileptic Disorders
- Vol. 25 (4) , 586-589
Competency‐based epilepsy training: A comparison between U.S.‐based milestones and ILAE curriculum
- 15 August 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 65 (3) , 424-430
Antiseizure medication reduction and withdrawal in children with drug‐resistant epilepsy after starting the ketogenic diet
Aim: To investigate the rate of successful withdrawal of antiseizure medication (ASM) after starting the ketogenic diet in children and identify predictive factors.Method: We retrospectively reviewed data of children with epilepsy, who were treated with the ketogenic diet for 6 months or longer at our institution, over a 5‐year period. We defined successful withdrawal of one or more medications as a time period of 3 months or more off this medication without restarting it or starting a new agent. Predictive clinical factors were investigated using binary multivariable logistic regression.Results: Seventy‐one children were included (28 females, 43 males; median age at seizure onset 5 months, median age at diet initiation 58.5 months, median duration of ketogenic diet 27.7 months). Reduction of one or more ASMs was attempted in 54 out of 71 (76%) children and was successful in 34 out of 54 (63%), including discontinuation of all ASMs in 13. Younger age at the start of the ketogenic diet was associated with higher odds of successful ASM withdrawal. ASM withdrawal was successful in 11 out of 19 children with less than 50% seizure reduction at 3 months.Interpretation: Reduction of ASM was achieved in two‐thirds of patients after the start of the ketogenic diet, where attempted, and can be successful even with little or unchanged seizure frequency while on the diet.
- 15 August 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 65 (3) , 424-430
Antiseizure medication reduction and withdrawal in children with drug‐resistant epilepsy after starting the ketogenic diet
Aim: To investigate the rate of successful withdrawal of antiseizure medication (ASM) after starting the ketogenic diet in children and identify predictive factors.Method: We retrospectively reviewed data of children with epilepsy, who were treated with the ketogenic diet for 6 months or longer at our institution, over a 5‐year period. We defined successful withdrawal of one or more medications as a time period of 3 months or more off this medication without restarting it or starting a new agent. Predictive clinical factors were investigated using binary multivariable logistic regression.Results: Seventy‐one children were included (28 females, 43 males; median age at seizure onset 5 months, median age at diet initiation 58.5 months, median duration of ketogenic diet 27.7 months). Reduction of one or more ASMs was attempted in 54 out of 71 (76%) children and was successful in 34 out of 54 (63%), including discontinuation of all ASMs in 13. Younger age at the start of the ketogenic diet was associated with higher odds of successful ASM withdrawal. ASM withdrawal was successful in 11 out of 19 children with less than 50% seizure reduction at 3 months.Interpretation: Reduction of ASM was achieved in two‐thirds of patients after the start of the ketogenic diet, where attempted, and can be successful even with little or unchanged seizure frequency while on the diet.
- Open Access
- 9 February 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (8) , 899-907
Fenfluramine as antiseizure medication for epilepsy
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a serotonergic mechanism. Therefore, it was initially used as an anorectic drug, given that impaired serotonin homeostasis may be associated with increased food intake. Although positive results were documented, cardiovascular concerns resulted in its temporary withdrawal. Nevertheless, a novel role in patients with epilepsy was later suggested by isolated clinical observations. The wide application of genetic testing allowed the classification (predominantly as Dravet syndrome) of patients in whom benefit was seen, while with the development of zebrafish models, its antiepileptic properties were confirmed at a molecular level. Data from randomized clinical trials have shown a beneficial effect of fenfluramine, as an adjunct therapy, on seizure control for children with Dravet syndrome, though there is still uncertainty about the impact on neurodevelopment in these patients. No signs of heart valve disease have been documented to date. Long‐term and appropriately designed clinical studies will verify whether fenfluramine is a therapeutic agent of high importance, living up to the promise shown so far. What this paper adds: Fenfluramine is a very promising repurposed therapy specifically for seizures in Dravet syndrome. The long‐term effect of fenfluramine on neurodevelopmental prognosis requires further investigation.
- 9 February 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (8) , 899-907
Open AccessFenfluramine as antiseizure medication for epilepsy
Fenfluramine hydrochloride has classically been described as acting pharmacologically through a serotonergic mechanism. Therefore, it was initially used as an anorectic drug, given that impaired serotonin homeostasis may be associated with increased food intake. Although positive results were documented, cardiovascular concerns resulted in its temporary withdrawal. Nevertheless, a novel role in patients with epilepsy was later suggested by isolated clinical observations. The wide application of genetic testing allowed the classification (predominantly as Dravet syndrome) of patients in whom benefit was seen, while with the development of zebrafish models, its antiepileptic properties were confirmed at a molecular level. Data from randomized clinical trials have shown a beneficial effect of fenfluramine, as an adjunct therapy, on seizure control for children with Dravet syndrome, though there is still uncertainty about the impact on neurodevelopment in these patients. No signs of heart valve disease have been documented to date. Long‐term and appropriately designed clinical studies will verify whether fenfluramine is a therapeutic agent of high importance, living up to the promise shown so far. What this paper adds: Fenfluramine is a very promising repurposed therapy specifically for seizures in Dravet syndrome. The long‐term effect of fenfluramine on neurodevelopmental prognosis requires further investigation.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
The impact of treatment with steroids on lung function of children with Duchenne muscular dystrophy: experience from a single centre
Background: Current evidence shows that steroids exert a beneficial effect on muscle strength of patients with Duchenne muscular dystrophy. Aim: To investigate the impact of treatment with steroids on lung function of children with Duchenne muscular dystrophy. Methods: Data from medical records of 60 boys with Duchenne was processed. The age at which treatment with steroids was suggested is considered as baseline time. Lung function was evaluated based on %pred values (for age, height and gender) of FVC, FEV1 and PEF. Results: Out of 49 boys initially offered treatment with steroids 29 finally started (14 prednisolone, 7 deflazacort and 7 methylprednisolone); 10 boys received therapy every day, 6 day by day and 11 10 days every month. The median duration of steroids use was 2 years. The 2 groups (steroids, non-steroids) did not differ significantly in baseline age (7.5 years in both groups), FEV1pred, FVCpred and PEFpred. One year after baseline time FEV1pred, FVCpred and PEFpred were not significantly different between two groups (0.91VS 0.83-p=0.3, 0.65 VS 0.71-p=0.93, 0.74 VS 0.65-p=0.23, respectively). Similarly, no significant differences in the afore-mentioned parameters were observed 3 years after baseline time (0.78VS0.75-p=0.62, 0.71VS0.67-p=0.53, 0.73VS0.68-p=0.53). The mean age by which pred values of the above spirometric parameters were <50% or <80% was similar between two groups. Conclusion: A clear beneficial effect of steroids on lung function of children with Duchenne was not identified. This might be due to the small sample size, age of steroids onset or to the duration of follow-up period.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
The impact of treatment with steroids on lung function of children with Duchenne muscular dystrophy: experience from a single centre
Background: Current evidence shows that steroids exert a beneficial effect on muscle strength of patients with Duchenne muscular dystrophy. Aim: To investigate the impact of treatment with steroids on lung function of children with Duchenne muscular dystrophy. Methods: Data from medical records of 60 boys with Duchenne was processed. The age at which treatment with steroids was suggested is considered as baseline time. Lung function was evaluated based on %pred values (for age, height and gender) of FVC, FEV1 and PEF. Results: Out of 49 boys initially offered treatment with steroids 29 finally started (14 prednisolone, 7 deflazacort and 7 methylprednisolone); 10 boys received therapy every day, 6 day by day and 11 10 days every month. The median duration of steroids use was 2 years. The 2 groups (steroids, non-steroids) did not differ significantly in baseline age (7.5 years in both groups), FEV1pred, FVCpred and PEFpred. One year after baseline time FEV1pred, FVCpred and PEFpred were not significantly different between two groups (0.91VS 0.83-p=0.3, 0.65 VS 0.71-p=0.93, 0.74 VS 0.65-p=0.23, respectively). Similarly, no significant differences in the afore-mentioned parameters were observed 3 years after baseline time (0.78VS0.75-p=0.62, 0.71VS0.67-p=0.53, 0.73VS0.68-p=0.53). The mean age by which pred values of the above spirometric parameters were <50% or <80% was similar between two groups. Conclusion: A clear beneficial effect of steroids on lung function of children with Duchenne was not identified. This might be due to the small sample size, age of steroids onset or to the duration of follow-up period.